Our team leverages core expertise in assay development, high-throughput screening (HTS), hit-to-lead medicinal chemistry, molecular design, in vitro ADME, and in vivo pharmacokinetics (PK) to expedite the drug discovery process. We apply integrated drug development capabilities in drug metabolism and pharmacokinetics, toxicology, bioanalysis, and analytical and formulation development to support development of drug candidates from hit identification to lead optimization and proof of principle.
We conduct medicinal chemistry–driven lead optimization campaigns to convert low potency/efficacy compounds with liabilities into preclinical candidates that can enter IND-enabling studies. We also support natural products discovery and hit generation using in-house focused libraries. Our scientists also provide computational chemistry and bioinformatics support.
Relying on a half-century of experience in the discovery and development of drug candidates, we work with pharmaceutical companies and government agencies to bring new medicines to market, and to ensure the safety and efficacy of those in the marketplace.